Abstract CT101: Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumorsNatalie Cook, Ruth Plummer, Helen Timmis et al.|Cancer Research|2024Cited by 3
CGE22-097: Mapping the Mutational Landscape in Patients With Advanced Malignancies Enrolled to Early Phase Clinical TrialsFarasat Kazmi, Sarah P. Blagden, Andrew Blake et al.|Journal of the National Comprehensive Cancer Network|2022Cited by 1